ArticleCureus2025
Gout Versus Pseudogout in the Medically Underserved Rio Grande Valley.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gout and pseudogout are inflammatory joint conditions, with gout being one of the most prevalent etiologies of chronic inflammatory arthritis in the United States. The patient population in the Rio Grande Valley (RGV) has a distinct demographic profile that warrants the exploration of various health conditions. The primary objective of this study was to expand the knowledge of orthopedics and determine if there were demographic disparities between gout and pseudogout in this community. We hypothesized that there would be demographic disparities between gout and pseudogout depending on age, sex, and ethnicity. Methods This was a retrospective chart review, and data was gathered from the University of Texas Rio Grande Valley (UTRGV) UTHealth electronic database from January 1, 2017, to January 1, 2024. We collected and analyzed medical charts of individuals who were diagnosed with gout or pseudogout using the International Classification of Diseases version 10 (ICD-10) diagnosis codes M10 for gout and M11.2 for pseudogout. Patients' characteristics were described by gout status using frequency (n) and percentage (%) for categorical variables. Results Individuals in age groups 40-65 years and greater than or equal to 65 years compared to patients aged less than 40 years old had significantly higher odds of having gout versus no gout. Women compared to men had 88% lower odds of having gout compared to no gout (odds ratio {OR}=0.12; 95% confidence interval {CI}: 0.08, 0.17; p<0.0001) and 83% lower odds of having gout compared to pseudogout (OR=0.17; 95% CI: 0.08, 0.39; p<0.0001). Hispanic or Latino ethnicity, compared to non-Hispanic and non-Latino ethnicity, had significantly lower odds of gout (OR=0.32; 95% CI: 0.23, 0.45; p<0.0001) and pseudogout (OR=0.30; 95% CI: 0.14, 0.65; p<0.0001) compared to no gout. Individuals classified as overweight or obese compared to normal-BMI patients had significantly higher odds of having gout compared to patients with no gout. Marital status was the only difference between univariable and multivariable analysis and was not significantly associated with gout status according to the multivariable model. Conclusion Individuals of various demographics in the underserved RGV community, and possibly demographically similar communities, may be at increased risk for gout or pseudogout. This warrants further research on these conditions in this region to further improve the knowledge and possibly prevent the numerous effects of these conditions on an individual's quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.